Buscar

01/11/2025 Amivantamab-Chemotherapy in Non-Small Cell Lung Cancer with EGFR Exon 20 Insertions: Impact of Treatment Crossover and Other Endpoints from the Phase III PAPILLON Study
Sanborn, RE, Zhou, CC, Tang, KJ, Cho, BC, Cheng, S, Popat, S, Ono, A, Lu, S, Majem, M, Aguilar, A, Campelo, MDG, Hayashi, H, Lee, KY, Lee, SH, Delmonte, A, Alatorre-Alexander, J, Richardson, G, Santos, V, Dooms, C, Sabari, JK, Shu, CA, Girard, N, Mansfield, AS, Park, K, Xia, YC, Bhattacharya, A, Buyukkaramikli, N, Perualila, N, Diels, J, Acharya, S, Chandler, C, Proskorovsky, I, Dearden, L, Wortman-Vayn, H, Mahadevia, PJ, Knoblauch, RE, Agrawal, T, Baig, M, Felip, E. Amivantamab-Chemotherapy in Non-Small Cell Lung Cancer with EGFR Exon 20 Insertions: Impact of Treatment Crossover and Other Endpoints from the Phase III PAPILLON Study. Targeted Oncology. 2025; 20(6)DOI:10.1007/s11523-025-01182-0. PMID:41184595. IF:4.000(Q2/3D).
01/11/2025 Magnitude of clinical benefit demonstrated in trials supporting FDA and EMA Approval of drugs for hematological malignancies, 2020-2024
Cardozo, AR, Kesselheim, A, Tibau, A. Magnitude of clinical benefit demonstrated in trials supporting FDA and EMA Approval of drugs for hematological malignancies, 2020-2024. ANNALS OF ONCOLOGY. 2025; 36DOI:10.1016/j.annonc.2025.08.1886. PMID:. IF:65.400(Q1/1D).
01/11/2025 Real-world outcomes after immunotherapy discontinuation in advanced melanoma: Insights from the GEM1801 study
Muñoz-Couselo, E, Berciano-Guerrero, MA, Crespo, G, Castaño, AG, Manzano, JL, Miguel, PAD, Rosa, CA, Cerezuela-Fuentes, P, Puértolas, T, Sanz, LG, Medina, J, Cunquero-Tomás, A, Majem, M, Fernández, LA, Espinosa, E, Bellido, L, Soria, A, Bujosa, A, Algarra, SM, Marquez-Rodas, I. Real-world outcomes after immunotherapy discontinuation in advanced melanoma: Insights from the GEM1801 study. ANNALS OF ONCOLOGY. 2025; 36DOI:10.1016/j.annonc.2025.08.2263. PMID:. IF:65.400(Q1/1D).
01/11/2025 Relevance of the CPS score and tumor nephrectomy in the SUNNIFORECAST trial comparing ipilimumab/nivolumab versus standard of care in non-clear cell renal cell cancer
Bergmann, L, Albiges, L, Ahrens, M, Goupil, MG, Boleti, E, Gravis, G, Flechon, A, Grimm, MO, Bedke, J, Barthelemy, P, Gauna, DEC, Gonzalez, BM, Ivanyi, P, Floercken, A, Rodriguez, CS, Rey, JPM, Gruenwald, V, Burkholder, I, Hartmann, A, Haanen, JBAG. Relevance of the CPS score and tumor nephrectomy in the SUNNIFORECAST trial comparing ipilimumab/nivolumab versus standard of care in non-clear cell renal cell cancer. ANNALS OF ONCOLOGY. 2025; 36DOI:10.1016/j.annonc.2025.08.3216. PMID:. IF:65.400(Q1/1D).
01/11/2025 International multicenter retrospective study of spindle cell/ sclerosing rhabdomyosarcoma (S-RMS): A PUSH platform study
Chen, TWW, Giani, C, Ljevar, S, Reinhorn, D, Denu, R, Bhadri, VA, Jaeger, R, Ibrahim, T, D'Ambrosio, L, Bae, S, Han, I, Garcia, AS, Abreu, MH, Ribeiro, MFSA, Mariuk-Jarema, A, Yang, V, Sbaraglia, M, Antonescu, C, Baldi, GG, Stacchiotti, S. International multicenter retrospective study of spindle cell/ sclerosing rhabdomyosarcoma (S-RMS): A PUSH platform study. ANNALS OF ONCOLOGY. 2025; 36DOI:10.1016/j.annonc.2025.08.3306. PMID:. IF:65.400(Q1/1D).
01/11/2025 Molecular landscape of IDH1/2-mutant gliomas: A Spanish multicentric cohort
Cerna, JGY, Mirallas, O, Garces, VN, Puerto, DAG, Velilla, G, Pastor, PG, Puga, TG, Salgado, MAV, Martínez, A, Gonzalez, AH, Sorolla, MA, Di Muzio, A, González, M, Martinez-Garcia, MJ, Villacampa, G, Balana, C, Galceran, JC, Dienstmann, R, Sanchez, JMS, Vieito, M. Molecular landscape of IDH1/2-mutant gliomas: A Spanish multicentric cohort. ANNALS OF ONCOLOGY. 2025; 36DOI:10.1016/j.annonc.2025.08.1270. PMID:. IF:65.400(Q1/1D).